1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Sanofi In Pole Position In Oral Type 1 Diabetes With Zynquista Filings

 
• By Kevin Grogan

The French drugmaker and partner Lexicon now have a PDUFA date of March 22 next year for their dual inhibitor of SGLT-1 and SGLT-2 which is well placed to become the first oral antidiabetic to get the green light for use by adults with the type 1 form of the disease, in combination with insulin.

Motor racing
Zynquista heads type 1 diabetes oral therapy race • Source: Shutterstock

The US FDA has begun its review of Sanofi and Lexicon Pharmaceuticals Inc.’s Zynquista (sotagliflozin), raising the firms' hopes that it will be the first oral drug approved to treat adults with type 1 diabetes.

The agency has accepted Sanofi’s regulatory filing as an add-on to insulin injections to help improve blood sugar control in type 1 diabetes patients

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D